XWELL, Inc.

As of August 15, 2022, XWELL, Inc. is considered risky due to its negative price-to-book value of -0.86 and a low EV to EBITDA ratio of 0.28, despite a high ROCE of 96.86%, while its P/E ratio of -0.3332 contrasts sharply with peers like Afya Ltd. at 11.81, and the company's stock has underperformed the S&P 500 with a year-to-date return of -27.54%.

As of October 5, 2023, XWELL, Inc. is considered undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, outperforming peers and the Sensex, indicating attractive investment potential.

As of November 1, 2023, there is insufficient technical data for XWELL, Inc. to determine a bullish or bearish outlook.

As of March 2022, the management team of XWELL, Inc. includes Mr. Bruce Bernstein (Independent Chairman), Mr. Douglas Satzman (CEO and Director), and Independent Directors Mr. Michael Lebowitz, Mr. Donald Stout, and Mr. Robert Weinstein. They oversee the company's strategic direction and operations.

XWELL, Inc. is a health and wellness holding company that provides spa services and luxury travel products, classified as a micro-cap company with a market cap of $4.73 million. As of March 2025, it reported net sales of $7 million and a net loss of $5 million.

As of Jun 18, XWELL, Inc. has a market capitalization of 4.73 million, with net sales of 32.19 million and a net profit of -18.73 million over the last four quarters. The company reported shareholder's funds of -0.79 million and total assets of 25.35 million as of Dec 24.